<DOC>
	<DOCNO>NCT02722161</DOCNO>
	<brief_summary>To investigate basic pharmacokinetics BI 1482694 , metabolite M1 M2 , [ 14C ] -radioactivity , include mass balance , excretion pathway metabolism follow single oral dose [ 14C ] BI 1482694 give healthy male volunteer</brief_summary>
	<brief_title>Olmutinib ( BI 1482694 ) ADME Study</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : Healthy male subject accord investigator 's assessment , base complete medical history include physical examination , vital sign ( BP [ Blood Pressure ] , PR [ Pulse Rate ] ) , 12lead ECG ( Electrocardiogram ) , clinical laboratory test Age 45 65 year ( incl . ) BMI ( Body Mass Index ) 18.5 29.9 kg/m2 ( incl . ) Signed date write informed consent prior admission study accordance GCP local legislation Subjects sexually active must use , partner , highly effective contraception time administration trial medication 4 month administration trial medication . Adequate method : Condoms plus use hormonal contraception female partner start least 2 month prior administration trial medication ( e.g. , implant , injectables , combine oral vaginal contraceptive , intrauterine device ) Condoms plus surgical sterilization ( vasectomy least 1 year prior enrolment ) Condoms plus surgically sterilised partner ( include hysterectomy ) Condoms plus intrauterine device Condoms plus partner nonchildbearing potential ( include homosexual men ) Subjects require use condom prevent unintended exposure partner study drug via seminal fluid . Male female condom must use together . Alternatively , true abstinence acceptable line subject 's preferred usual lifestyle . If subject usually sexually active becomes active , partner , must comply contraceptive requirement detail . Exclusion criterion : Any find medical examination ( include BP , PR ECG ) deviate normal judge clinically relevant investigator Any laboratory value outside reference range investigator considers clinical relevance Any evidence concomitant disease judge clinically relevant investigator Clinically significant gastrointestinal , hepatic , renal , respiratory ( include limit interstitial lung disease ) , cardiovascular , metabolic , immunological hormonal disorder Cholecystectomy and/or surgery gastrointestinal tract could interfere pharmacokinetics trial medication ( except appendectomy simple hernia repair ) Diseases central nervous system ( include limit kind seizure stroke ) , relevant neurological psychiatric disorder History relevant orthostatic hypotension , faint spell , blackout Chronic relevant acute infection History relevant allergy hypersensitivity ( include allergy trial medication excipients ) Intake drug long halflife ( 24 h ) within 30 day less 10 halflives respective drug prior administration trial medication Within 10 day prior administration trial medication , use drug might reasonably influence result trial might prolong QT/heart ratecorrected QT interval Participation another trial investigational drug administer within 60 day prior plan administration trial medication Smoker ( 5 cigarette 1 cigar 1 pipe per day ) Inability refrain smoke specify trial day Average intake 24 unit alcohol per week ( 1 unit alcohol equal approximately 250 mL beer , 100 mL wine 35 mL spirit ) Drug abuse positive drug screen Blood donation 100 mL within 30 day prior administration trial medication intend donation trial Inability comply dietary regimen trial site A marked baseline prolongation QT/heart ratecorrected QT interval ( heart ratecorrected QT interval follow formula Fridericia repeatedly great 450 m ) relevant ECG find screen A history additional risk factor Torsades de Pointes ( heart failure , hypokalemia , family history Long QT Syndrome ) Subject assess unsuitable inclusion investigator , instance , consider able understand comply study requirement , condition would allow safe participation study In addition , follow trialspecific exclusion criterion apply : Radiation exposure , include present study , exclude background radiation include diagnostic xrays medical exposure , exceed 5 mSv last 12 month 10 mSv last 10 year . No occupationally expose worker , define Ionising Radiation Regulations 1999 , shall participate study Irregular defecation pattern ( less mean one bowel movement day ) Platelet count &lt; 100 * 10^9 cells/L</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>